Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.85)
# 680
Out of 5,113 analysts
216
Total ratings
56.69%
Success rate
7.57%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $24 → $27 | $26.40 | +2.29% | 16 | Jan 27, 2026 | |
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $347.94 | -9.47% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $105.47 | +6.19% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,050.21 | -6.21% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $140.00 | -3.57% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $763.56 | -3.09% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $222.87 | +12.17% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $473.40 | +2.45% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $55.39 | -0.70% | 16 | Apr 23, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $54.46 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $107.58 | -20.99% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $134.83 | +22.38% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $29.78 | -32.84% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $173.68 | +3.64% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $14.28 | +320.17% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.74 | +302.74% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.37 | +559.34% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $63.73 | +49.07% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $8.48 | +135.87% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $67.93 | +7.46% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.93 | +523.12% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.57 | -41.63% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.10 | +2,172.73% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $144.81 | +162.41% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $103.41 | -20.70% | 5 | Jan 16, 2019 |
Pfizer
Jan 27, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $26.40
Upside: +2.29%
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $347.94
Upside: -9.47%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $105.47
Upside: +6.19%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,050.21
Upside: -6.21%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $140.00
Upside: -3.57%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $763.56
Upside: -3.09%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $222.87
Upside: +12.17%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $473.40
Upside: +2.45%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $55.39
Upside: -0.70%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $54.46
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $107.58
Upside: -20.99%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $134.83
Upside: +22.38%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $29.78
Upside: -32.84%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $173.68
Upside: +3.64%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $14.28
Upside: +320.17%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.74
Upside: +302.74%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.37
Upside: +559.34%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $63.73
Upside: +49.07%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $8.48
Upside: +135.87%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $67.93
Upside: +7.46%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.93
Upside: +523.12%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.57
Upside: -41.63%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.10
Upside: +2,172.73%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $144.81
Upside: +162.41%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $103.41
Upside: -20.70%